Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti‐D immunoglobulin: more questions than answers

Belinda M. Kumpel(NHS Blood and Transplant)

Vox Sanguinis

June 20, 2007

10.1111/j.1423-0410.2007.00945.x

Cited by 97

Related Papers

A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy

|Blood|2013|226

Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity.

|PubMed|1994|107

Mechanism of anti-D-mediated immune suppression – a paradox awaiting resolution?

|Trends in Immunology|2001|103

Human monoclonal anti‐D antibodies. I. THEIR PRODUCTION, SEROLOGY, QUANTITATION AND POTENTIAL USE AS BLOOD GROUPING REAGENTS

|British Journal of Haematology|1989|93

Protein-sequence studies on Rh-related polypeptides suggest the presence of at least two groups of proteins which associate in the human red-cell membrane

|Biochemical Journal|1988|86